Chinese (SSE) Drug Retail Industry Analysis

Industry Valuation and Performance

Has the Chinese Drug Retail Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 26 Aug 2026	CN¥85.5b	CN¥123.3b	CN¥4.3b	24.8x	20x	0.7x
Fri, 24 Jul 2026	CN¥81.2b	CN¥122.8b	CN¥4.2b	23.5x	19.3x	0.7x
Sun, 21 Jun 2026	CN¥75.6b	CN¥122.8b	CN¥4.2b	22.4x	18x	0.6x
Tue, 19 May 2026	CN¥84.7b	CN¥123.1b	CN¥4.2b	24.9x	20.3x	0.7x
Thu, 16 Apr 2026	CN¥89.0b	CN¥121.3b	CN¥3.6b	25.1x	24.8x	0.7x
Sat, 14 Mar 2026	CN¥92.0b	CN¥121.2b	CN¥3.6b	26x	25.6x	0.8x
Mon, 09 Feb 2026	CN¥96.2b	CN¥121.2b	CN¥3.6b	27.7x	26.7x	0.8x
Wed, 07 Jan 2026	CN¥89.5b	CN¥121.2b	CN¥3.6b	27.5x	24.9x	0.7x
Fri, 05 Dec 2025	CN¥90.1b	CN¥121.2b	CN¥3.6b	28.8x	25x	0.7x
Sun, 02 Nov 2025	CN¥89.9b	CN¥121.1b	CN¥3.5b	28.8x	25.7x	0.7x
Tue, 30 Sep 2025	CN¥87.6b	CN¥120.6b	CN¥3.3b	30.3x	26.3x	0.7x
Thu, 28 Aug 2025	CN¥89.6b	CN¥120.5b	CN¥3.2b	30.8x	28.4x	0.7x
Sat, 26 Jul 2025	CN¥92.7b	CN¥120.4b	CN¥3.3b	31.9x	28.5x	0.8x
Mon, 23 Jun 2025	CN¥89.9b	CN¥120.4b	CN¥3.3b	30x	27.6x	0.7x
Wed, 21 May 2025	CN¥96.4b	CN¥120.4b	CN¥3.3b	31.5x	29.6x	0.8x
Fri, 18 Apr 2025	CN¥94.0b	CN¥121.0b	CN¥3.9b	23.2x	24.2x	0.8x
Sun, 16 Mar 2025	CN¥90.3b	CN¥121.0b	CN¥3.9b	20.4x	23.1x	0.7x
Tue, 11 Feb 2025	CN¥85.2b	CN¥121.0b	CN¥3.9b	19.3x	21.8x	0.7x
Thu, 09 Jan 2025	CN¥81.8b	CN¥121.0b	CN¥3.9b	19x	21x	0.7x
Sat, 07 Dec 2024	CN¥89.7b	CN¥121.0b	CN¥3.9b	19.9x	23x	0.7x
Mon, 04 Nov 2024	CN¥91.6b	CN¥121.0b	CN¥3.9b	21.1x	23.5x	0.8x
Wed, 02 Oct 2024	CN¥90.4b	CN¥119.6b	CN¥4.3b	20.6x	20.9x	0.8x
Fri, 30 Aug 2024	CN¥69.1b	CN¥118.5b	CN¥4.8b	15.5x	14.5x	0.6x
Sun, 28 Jul 2024	CN¥75.4b	CN¥118.4b	CN¥4.8b	17.1x	15.7x	0.6x
Tue, 25 Jun 2024	CN¥90.3b	CN¥118.4b	CN¥4.8b	21.3x	18.8x	0.8x
Thu, 23 May 2024	CN¥126.4b	CN¥118.4b	CN¥4.8b	26.1x	26.4x	1.1x
Sat, 20 Apr 2024	CN¥119.8b	CN¥114.8b	CN¥5.2b	22.4x	23x	1x
Mon, 18 Mar 2024	CN¥118.0b	CN¥115.9b	CN¥5.8b	19.8x	20.3x	1x
Wed, 14 Feb 2024	CN¥122.1b	CN¥115.9b	CN¥5.8b	20.5x	21x	1.1x
Fri, 12 Jan 2024	CN¥128.1b	CN¥116.0b	CN¥5.7b	22.1x	22.3x	1.1x
Sun, 10 Dec 2023	CN¥124.9b	CN¥116.0b	CN¥5.7b	22.5x	21.8x	1.1x
Tue, 07 Nov 2023	CN¥121.1b	CN¥115.4b	CN¥5.7b	21.9x	21.3x	1x
Thu, 05 Oct 2023	CN¥120.4b	CN¥113.6b	CN¥5.7b	23.1x	21.2x	1.1x
Sat, 02 Sep 2023	CN¥122.2b	CN¥113.2b	CN¥5.7b	24.2x	21.5x	1.1x

Current Industry PE

Investors are pessimistic on the Chinese Drug Retail industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 19.8x which is lower than its 3-year average PE of 22.8x.

The industry is trading close to its 3-year average PS ratio of 0.81x.

Past Earnings Growth

The earnings for companies in the Drug Retail industry have declined 9.5% per year over the last three years.
Meanwhile revenues for these companies have grown 2.7% per year.
This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Chinese Drug Retail compare with similar industries?


CN Market	-4.43%
Consumer Staples	-1.21%
Food and Staples Retail	-3.29%
Drug Retail	-0.97%
Big Box Super Stores	3.35%
Food Distributors	-1.31%
Food Retail	-6.00%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
603233 DaShenLin Pharmaceutical Group	CN¥18.29	2.1% +CN¥432.8m	9.2%	PE15.3x
002727 Yixintang Pharmaceutical Group	CN¥11.83	2.4% +CN¥160.8m	-19.7%	PE24.3x
301017 ShuYu Civilian Pharmacy	CN¥13.27	1.5% +CN¥77.1m	8.2%	PE51.9x
605266 Jianzhijia Pharmaceutical Chain Group	CN¥16.81	1.9% +CN¥45.9m	-19.7%	PE16.5x
600833 Shanghai No.1 PharmacyLtd	CN¥10.75	0.6% +CN¥13.4m	-17.9%	PE31.4x

Company

Last Price

Valuation

603233 DaShenLin Pharmaceutical Group

CN¥18.29

2.1%
+CN¥432.8m

9.2%

PE15.3x

002727 Yixintang Pharmaceutical Group

CN¥11.83

2.4%
+CN¥160.8m

-19.7%

PE24.3x

301017 ShuYu Civilian Pharmacy

CN¥13.27

1.5%
+CN¥77.1m

8.2%

PE51.9x

605266 Jianzhijia Pharmaceutical Chain Group

CN¥16.81

1.9%
+CN¥45.9m

-19.7%

PE16.5x

600833 Shanghai No.1 PharmacyLtd

CN¥10.75

0.6%
+CN¥13.4m

-17.9%

PE31.4x

Second quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2026 results: EPS: CN¥0.36 (up from CN¥0.30 in 2Q 2025). Revenue: CN¥7.02b (up 6.9% from 2Q 2025). Net income: CN¥415.6m (up 23% from 2Q 2025). Profit margin: 5.9% (up from 5.1% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) exceeded analyst estimates by 6.8%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.

Chinese (SSE) Drug Retail Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

Second quarter 2026 earnings released: EPS: CN¥0.03 (vs CN¥0.028 in 2Q 2025)

Second quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind

LBX Pharmacy Chain Joint Stock Company (SHSE:603883) announces an Equity Buyback for CNY 80 million worth of its shares.

Anhui Huaren Health Pharmaceutical Co., Ltd. announced that it expects to receive CNY 709.0743 million in funding

Investor sentiment improves as stock rises 23%

Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) announces an Equity Buyback for CNY 300 million worth of its shares.

Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. to Report First Half, 2026 Results on Aug 25, 2026

Yixintang Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 27, 2026

Jianzhijia Pharmaceutical Chain Group Co., Ltd. to Report First Half, 2026 Results on Aug 27, 2026